1. Home
  2. GKOS vs MSGS Comparison

GKOS vs MSGS Comparison

Compare GKOS & MSGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • MSGS
  • Stock Information
  • Founded
  • GKOS 1998
  • MSGS 1879
  • Country
  • GKOS United States
  • MSGS United States
  • Employees
  • GKOS N/A
  • MSGS N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • MSGS Services-Misc. Amusement & Recreation
  • Sector
  • GKOS Health Care
  • MSGS Consumer Discretionary
  • Exchange
  • GKOS Nasdaq
  • MSGS Nasdaq
  • Market Cap
  • GKOS 5.1B
  • MSGS 4.5B
  • IPO Year
  • GKOS 2015
  • MSGS N/A
  • Fundamental
  • Price
  • GKOS $89.91
  • MSGS $191.78
  • Analyst Decision
  • GKOS Strong Buy
  • MSGS Buy
  • Analyst Count
  • GKOS 13
  • MSGS 5
  • Target Price
  • GKOS $135.15
  • MSGS $252.60
  • AVG Volume (30 Days)
  • GKOS 1.1M
  • MSGS 143.1K
  • Earning Date
  • GKOS 04-30-2025
  • MSGS 05-02-2025
  • Dividend Yield
  • GKOS N/A
  • MSGS N/A
  • EPS Growth
  • GKOS N/A
  • MSGS N/A
  • EPS
  • GKOS N/A
  • MSGS 0.20
  • Revenue
  • GKOS $404,523,000.00
  • MSGS $1,062,514,000.00
  • Revenue This Year
  • GKOS $27.84
  • MSGS N/A
  • Revenue Next Year
  • GKOS $27.88
  • MSGS $7.07
  • P/E Ratio
  • GKOS N/A
  • MSGS $960.57
  • Revenue Growth
  • GKOS 23.92
  • MSGS 14.64
  • 52 Week Low
  • GKOS $77.10
  • MSGS $173.26
  • 52 Week High
  • GKOS $163.71
  • MSGS $237.99
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 45.80
  • MSGS 50.67
  • Support Level
  • GKOS $84.26
  • MSGS $184.63
  • Resistance Level
  • GKOS $92.27
  • MSGS $193.98
  • Average True Range (ATR)
  • GKOS 3.94
  • MSGS 3.93
  • MACD
  • GKOS 0.57
  • MSGS 0.32
  • Stochastic Oscillator
  • GKOS 58.87
  • MSGS 59.78

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About MSGS Madison Square Garden Sports Corp. (New)

Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.

Share on Social Networks: